Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert Panel-Reference-Cited by-同舟云学术

Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert Panel

Published:2024-07-22 Issue:9 Volume:15 Page:1963-1977
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Candido Riccardo,Di Loreto Chiara,Desenzani Paolo,Pantanetti Paola,Romano Cristina,Settembrini Silvio,Solerte Sebastiano Bruno,Fadini Gian Paolo^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13300-024-01625-3.pdf

Reference38 articles.

1. Aroda VR, Rosenstock J, Terauchi Y, et al. Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–32. https://doi.org/10.2337/dc19-0749.

2. Rodbard HW, Dougherty T, Taddei-Allen P. Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. Am J Manag Care. 2020;26(16 Suppl):S335–43. https://doi.org/10.37765/ajmc.2020.88554.

3. Andersen A, Knop FK, Vilsbøll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs. 2021;81(9):1003–30. https://doi.org/10.1007/s40265-021-01499-w.

4. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. https://doi.org/10.1126/scitranslmed.aar7047.

5. Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263–77. https://doi.org/10.1111/dom.14054.